Oyster Point completes enrollment in dry eye nasal spray trial

Enrollment has been completed in a pivotal phase 3 trial of OC-01 nasal spray for the treatment of signs and symptoms of dry eye disease, Oyster Point Pharma announced in a press release.
The randomized, double-masked, placebo-controlled ONSET-2 trial includes 758 subjects at 22 centers in the U.S. It is investigating a 0.6 mg/mL dose and a 1.2 mg/mL dose of OC-01 nasal spray compared with placebo nasal spray, the release said.
The trial’s primary endpoint is the assessment of tear production measured by the percentage of subjects with a (Read more...)

Full Story →